Phase II Dose Ranging Study of Artesunate

Status Completed

Clinical Trial Summary

The purpose of this study is to compare four regimens using US FDA GMP intravenous artesunate for the treatment of uncomplicated Plasmodium falciparum malaria to identify the most effective treatment regimen as determined by rapidity of parasite clearance by microscopy.

Clinical Trial Description

To compare the efficacy and tolerability of intravenous artesunate for the initial treatment of uncomplicated Plasmodium falciparum malaria at doses that bracket anticipated clinical doses (2.4 mg/kg once daily for 3 days; or 2.4 mg/kg initially, at 12 hours on Day 0, and then daily on Day 1 and 2) and thereby establish the safest, highly efficacious dosing regimen for use in future clinical trials. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00459615
Study type	Interventional
Source	Walter Reed Army Institute of Research (WRAIR)
Contact
Status	Completed
Phase	Phase 2
Start date	April 2007
Completion date	January 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00440752` - The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance	N/A
Completed	`NCT01144702` - Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum	Phase 2/Phase 3
Terminated	`NCT00400101` - Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides	Phase 1
Completed	`NCT01350856` - Tracking Resistance to Artemisinin (TRAC)	Phase 4
Completed	`NCT00859807` - A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects	Phase 4
Completed	`NCT04222088` - TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014
Completed	`NCT01115439` - Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria	N/A
Completed	`NCT00282919` - A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria	Phase 2
Completed	`NCT04422015` - Biological Mechanisms in Afebrile P. Falciparum Malaria
Completed	`NCT00894374` - Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects	Phase 1
Completed	`NCT00894660` - A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects	Phase 1
Completed	`NCT00493363` - Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia	N/A
Completed	`NCT00158548` - ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan	Phase 3
Withdrawn	`NCT04289558` - Nitrite Infusion in Children With Malaria	Phase 1
Completed	`NCT01374126` - Azithromycin Combination Therapy for the Treatment of Severe Malaria	Phase 2
Completed	`NCT00722150` - Artemisinin Resistance in Cambodia II	N/A
Completed	`NCT00157833` - A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.	N/A
Completed	`NCT00513669` - Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania	Phase 1
Completed	`NCT00442377` - Study to Investigate the Induction of an Protective Immune Response to Malaria	N/A
Completed	`NCT00403260` - Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients	Phase 3